Following a recent conference where the subject of punctal occlusion treatment (POT) came up on more than one occasion it was felt worthwhile to look again at a 2017 clinical trial investigating the effect of such a treatment on contact lens discomfort. These results indicated that POT can produce statistically significant improvements in the frequency, severity, and overall sum of subjective symptoms associated with dryness among SCL wearers, while the categorical InflammaDry (ID) test showed improvement although no statistically significant change was found. These results indicate that POT is a promising option for SCL wearers who have dryness complaints.
I would encourage you to look especially at the CLDEQ-8 results and Additional Analysis. It is important to note that all subjects were only included for POT after establishing there was no active ocular surface inflammation by the ID test at the point of treatment, not the same date as baseline. The trial was jointly funded by a grant from Positive Impact and Beaver Visitec International. Further product information can be obtained from Positive Impact by email
IN PROGRESS: LISTING AND LINKS TO PRESCRIPTION ONLY OCULAR MEDICINES 